America's Innovation Engine: Small and Mid-Sized Biotechs Drive U.S. Clinical Trials, FDA Filings

Key Takeaways

• Small and mid-sized biotechs represent approximately 99% of U.S. biotech business establishments and account for 71% of total industry employment.
• These companies lead approximately 50% of all industry-sponsored clinical trials and originate 54% of FDA filings, demonstrating their outsized role in drug development pipelines.
• More than 35% of biotechs operate with less than one year of cash on hand, underscoring reliance on investor capital and strategic partnerships for survival.
• Approximately 90% of biotechs outsource manufacturing to contract development and manufacturing organizations (CDMOs) to concentrate resources on research and development.
• Policy frameworks must support the full biotech ecosystem without undermining the innovation capacity of smaller companies.

Why Small and Mid-Sized Biotechs Matter to Your Pipeline

For business development, R&D, and regulatory teams, this BIO whitepaper reinforces a critical reality: a substantial portion of future pipeline value originates in smaller biotech companies. These firms translate early-stage discoveries—often emerging from academic research and federal investment—into clinical candidates and marketed therapies across oncology, rare disease, and chronic conditions.

Understanding the operational constraints of smaller partners is essential for deal structuring and execution. Limited cash reserves, heavy reliance on outsourced manufacturing, and focused pipeline portfolios (typically 1–5 programs per company) shape timelines, manufacturing strategy, and trial feasibility.

The Economics of Early Innovation

Across more than 2,000 U.S. biotech companies, approximately 300 are publicly listed. Small and mid-sized companies—typically employing fewer than 1,500 people and pursuing 1–5 research programs—operate without revenue and depend on investor capital and partnerships. The cash constraint is acute: more than 35% of biotechs held less than one year of operating capital in 2023, compared to 18% in 2021.

Manufacturing outsourcing is nearly universal. Approximately 90% of biotechs rely on CDMOs to manage production, allowing internal teams to focus on discovery and development.

Frequently Asked Questions

What percentage of clinical trials are led by small and mid-sized biotechs?

According to BIO, small and mid-sized biotech companies lead approximately 50% of all industry-sponsored clinical trials, demonstrating their central role in translating science into human studies.

How do small biotechs fund operations and development?

Small biotechs rely heavily on investor capital, strategic partnerships, and licensing agreements. More than 35% operate with less than one year of cash on hand, making continuous fundraising and partnership activity essential to survival and progress.

Why do most biotechs outsource manufacturing?

Approximately 90% of biotechs outsource manufacturing to CDMOs to reduce capital expenditure, avoid fixed overhead, and redirect limited resources toward research and development—the core value driver for early-stage companies.

What share of new FDA filings originate from small and mid-sized companies?

Small and mid-sized biotechs originate 54% of FDA filings, underscoring their disproportionate contribution to the regulatory pipeline despite representing a minority of industry revenue.

Source: BIO (Biotechnology Innovation Organization). "America's Innovation Engine: The Power of Small and Mid-Sized Biotechs." www.bio.org